Ategra Capital Management, LLC Abb Vie Inc. Transaction History

Ategra Capital Management, LLC

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Feb 13, 2025	SELL	$154.79 - $180.76 $1.08 Million - $1.26 Million	-6,987 Closed	0 $0
Q4 2023 Feb 13, 2025	BUY	$137.6 - $154.97 $48,022 - $54,084	349 Added 5.26%	6,987 $1.08 Billion
Q3 2023 Feb 13, 2025	BUY	$133.59 - $154.65 $403,174 - $466,733	3,018 Added 83.37%	6,638 $989 Million
Q2 2023 Feb 13, 2025	BUY	$132.51 - $164.9 $78,710 - $97,950	594 Added 19.63%	3,620 $488 Million
Q3 2021 Feb 13, 2025	SELL	$106.4 - $120.78 $10,427 - $11,836	-98 Reduced 3.14%	3,026 $326 Million
Q2 2021 Feb 13, 2025	BUY	$105.21 - $117.21 $2,630 - $2,930	25 Added 0.81%	3,124 $352 Million
Q1 2021 Feb 13, 2025	BUY	$102.3 - $112.62 $8,184 - $9,009	80 Added 2.65%	3,099 $335 Million
Q4 2020 Feb 13, 2025	BUY	$80.49 - $108.67 $4,185 - $5,650	52 Added 1.75%	3,019 $323 Million
Q3 2020 Feb 13, 2025	SELL	$85.91 - $100.83 $74,569 - $87,520	-868 Reduced 22.63%	2,967 $260 Million
Q2 2020 Feb 13, 2025	BUY	$73.37 - $98.18 $40,206 - $53,802	548 Added 16.67%	3,835 $377 Million
Q1 2020 Feb 13, 2025	BUY	$64.5 - $97.79 $19,479 - $29,532	302 Added 10.12%	3,287 $250 Million
Q4 2019 Feb 13, 2025	BUY	$72.13 - $90.25 $4,039 - $5,054	56 Added 1.91%	2,985 $264 Million
Q3 2019 Feb 13, 2025	SELL	$62.98 - $75.72 $47,927 - $57,622	-761 Reduced 20.62%	2,929 $222 Million
Q2 2019 Feb 13, 2025	SELL	$65.7 - $83.98 $6,570 - $8,398	-100 Reduced 2.64%	3,690 $268 Million
Q1 2019 Feb 13, 2025	BUY	$77.14 - $90.79 $292,360 - $344,094	3,790 New	3,790 $305 Million

4,092

1.28B

16.7M

15M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $355B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Ategra Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Ategra Capital Management, LLC with notifications on news.